Sodium Acetate Injection — supply status, manufacturers & alternatives

Sodium Acetate Injection

—

In supply · Australia

In supply · 🇦🇺 Australia · short in🇨🇦 CA

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Marketing-authorisation holders
Active ingredient (INN)	Sodium Acetate Injection
Therapeutic category	Auto-created by Health Canada — Recalls and Safety Alerts scraper
Controlled substance	No

Registrations on file	3

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Recalls official enforcement reports

🇨🇦

Sodium Acetate Injection

Marketed health products · Mar 2022

Class ?details ↗

🇨🇦

Sodium Acetate Injection

Drugs and health products · Mar 2022

Class Idetails ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders3 registrations · 3 MA holders

Product	Strength	Form	Market	MA holder	Status
Sodium Acetate Injection, Usp	—	solution	🇨🇦 CA	FRESENIUS KABI CANADA LTD	Active
Sodium Acetate Injection Usp	—	solution	🇨🇦 CA	OMEGA LABORATORIES LIMITED	Active
16.4% Sodium Acetate Injection, Usp	16.4%	solution	🇨🇦 CA	BAXTER CORPORATION	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.